'Global Issues in the Commercialization of Tissue Engineering' Instructional Webcast to Take Place March 30th, 2005.

LARCHMONT, N.Y. -- A virtual seminar on "Global Issues in the Commercialization of Tissue Engineering," presented by Genetic Engineering News (www.GENseminars.com), and Tissue Engineering journal (www.liebertpub.com/ten), will be held on March 30, 2005, at 12 pm EST. This live webcast will focus on the global complexities involved in moving the commercialization of tissue-engineering products and processes forward.

Presenting will be David Williams, DSc, FREng, Director of the UK Centre for Tissue Engineering at the University of Liverpool. Professor Williams, who leads a large research team in the UK, has an extensive background in advising the European Union on complex regulatory and risk-analysis issues within tissue engineering and medical technology. He is also well known for analyzing political and technological factors in parts of Asia.

Peter C. Johnson, M.D., Executive Vice President and Chief Medical Officer, Strategic Development, at Icoria, Inc., will moderate the event.

This 90-minute virtual seminar will review and analyze key issues in a global context:

--Tissue Engineering: What's Holding it Back? What Propels it Forward?

--The Big Picture: How Will Tissue Engineering impact health? The economy?

--How can we best make sense of regulation and clinical testing from a global perspective?

--A perspective on an overall systems approach to tissue-engineering products and processes will also be offered.

"Tissue engineering is one of the most promising areas of biotechnology research," says John Sterling, editor-in-chief of Genetic Engineering News. "Nevertheless, there remain a number of scientific, technical, and regulatory issues that need to be resolved, and this seminar offers a unique opportunity to address these considerations."

Registrations for "Global Issues in the Commercialization of Tissue Engineering" are limited to ensure interactive participation. Following the presentation will be an extensive Q&A session, with worldwide participation. To register online, and for further information, visit www.GENseminars.com.

Genetic Engineering News (www.genengnews.com), the most widely read publication in the biotechnology industry, and Tissue Engineering (www.liebertpub.com/ten), an authoritative peer-reviewed journal focusing on engineering and applications of new biologic tissue, are published by Mary Ann Liebert, Inc., a privately held, fully integrated media company known for developing authoritative journals in cutting-edge areas of bioscience and medicine, engineering, law, and business.